Tania Small, MD is Global Medical Affairs Therapeutic Area Head of Oncology at GSK and Chair of the diversity, equity, and inclusion R&D Council. She has built and leads an organization of approximately 500 professionals focused on patient-driven science, breaking down the barriers to access and driving impactful and innovative solutions to improve the outcome of individuals with cancers. Dr. Small was trained in Hematology/Oncology and bone marrow transplant at Columbia University, New York Presbyterian where she also completed a genetic research fellowship. She subsequently continued her focused on both hematology and stem cell transplant. She has done research in oncology, hematology, gene therapy and stem cell transplantation, and received grants from the U.S. National Institutes of Health (NIH) for her translational research in gene therapy and regenerative medicine. In previous roles with Novartis Oncology and Ipsen, Dr. Small successfully led the launch programs of multiple oncology therapies while overseeing both clinical development programs as well as medical affairs programs. She has also led many patient-centered and diversity initiatives in previous roles, working closely with the U.S. FDA, Congress and the American Society of Clinical Oncology (ASCO) to improve the diversity enrollment into oncology clinical trials and elderly programs. She is passionate about creating a world class oncology program that will successfully deliver the transformational medicines needed to revolutionize the experience and outcomes of patients.